Subject of the day
CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $588.99M | +65.3% | |
| Operating income | $257.78M | +44.2% | |
| Net income | $71.41M | +17.5% | |
| Cash from ops | $143.60M | +33.6% |
$31.49
· +0.00 (+0.0%)
| 52w hi | $31.49 |
|---|---|
| 52w lo | $19.13 |
| Vol | 0 |
| As of | Jul 21 |
Our score +0.47
| Short | +0.27 |
|---|---|
| Medium | +0.60 |
| Long | +0.60 |
computed 2026-08-13
Catalyst Pharmaceuticals Inc
Healthcare · Biotechnology
| Market cap | $3.85B |
|---|---|
| Enterprise value | $3.10B |
| Trailing P/E | 18.20x |
| Forward P/E | 9.90x |
| EV / EBITDA | 10.14x |
| P / S (ttm) | 6.46x |
| Profit margin | 37.1% |
| Return on equity | 24.5% |
| Revenue growth | +5.6% |
| Earnings growth | +11.1% |
| Debt / equity | 0.27 |
| Beta vs SPX | 0.92 |
|---|---|
| Corr SPX | 0.40 |
| Annual vol | 37.7% |
| Annual ret | +41.1% |
| Sharpe | 1.09 |
| Max DD | -27.3% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.31 | |
| Sector | +0.12 | |
| Technical | +0.24 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Jul 21 | $31.49 | $31.49 | $31.49 | $31.49 | 0 |
| Jul 20 | $31.49 | $31.49 | $31.49 | $31.49 | 0 |
| Jul 17 | $31.49 | $31.49 | $31.49 | $31.49 | 0 |
| Jul 16 | $31.49 | $31.49 | $31.49 | $31.49 | 0 |
| Jul 15 | $31.49 | $31.49 | $31.49 | $31.49 | 0 |